Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The selection of adequate dialysis therapy is crucial to manage patients with end-stage kidney disease (ESKD). Peritoneal dialysis (PD) provides gradual ultrafiltration rate compared to hemodialysis (HD). Whether this difference in ultrafiltration rate affects cardiac function in patients with ESKD remains to be fully elucidated.
The current study retrospectively analyzed 52 patients with ESKD who were hospitalized due to commence adequate dialysis therapy (2019.01.01-2024.4.30). After hospitalization, either PD or HD was commenced according to each physician’s discretion. Cardiac function was evaluated by echocardiography at baseline and 10 months (interquartile range=5-16 months) after the commencement of dialysis therapy. Clinical demographics and echocardiographic indices were compared in those who received PD and HD.
PD was selected in 27% of study subjects (=14/52). There were no significant differences in baseline clinical characteristics (age: p=0.053, male: p=0.977, BMI: p=0.221, T2DM: p=0.920) between the two groups. Almost 50 % of both groups concomitantly exhibited coronary artery disease (p=0.866). In addition, patients receiving PD were less likely to exhibit atrial fibrillation (47.4% vs. 7.1%, p=0.004). Among patients receiving HD, 47.4% had an arteriovenous fistula as their vascular access. Biochemistry data revealed a lower frequency of anemia in patients receiving PD (hemoglobin: 9.6±1.4 vs. 10.6±1.2, p=0.023). Baseline echocardiographic indices [left ventricular ejection fraction (LVEF), left ventricular diastolic/systolic diameter, left atrial volume index] did not differ between patients with PD and HD (Table). However, on serial echocardiographic analysis, following the adjustments of baseline clinical characteristics (age, gender, atrial fibrillation, hemoglobin, arteriovenous fistula, and baseline LVEF), the commencement of PD was associated with a greater increase in LVEF [0 vs +5.2%, p=0.0002*). Furthermore, in patients receiving HD, LAVI did not change during the course of the study, whereas LAVI was smaller at the follow-up period in those receiving PD (Figure).
In the current study, PD favorably improved cardiac function, accompanied by the reduction of atrial sizes. Given that PD enables to undergo continuous as well as gradual ultrafiltration control, these PD-derived effects may induce the improvement of cardiac functions in patients with ESKD.
